deltatrials
Completed PHASE2 INTERVENTIONAL 3-arm NCT04084444

Safety and Efficacy of T8 on Treating Chronic Abnormal Immune Activation in HIV/AIDS Patients

Efficacy and Safety of T8 on Treating Chronic Abnormal Immune Activation in HIV/AIDS Patients: A Multicenter, Randomized, Double-blind, Dose-finding, Placebo-controlled Study

Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd

Conditions Chronic Abnormal Immune Activation in HIV/AIDS
Interventions Placebo T8 tablet 0.5mg T8 tablet 1mg
Updated 9 times since 2019 Last updated: Mar 28, 2023 Started: Dec 25, 2019 Primary completion: Jul 5, 2022 Completion: Jul 5, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Chronic Abnormal Immune Activation in HIV/AIDS, this trial is completed. The trial is conducted by Shanghai Pharmaceuticals Holding Co., Ltd and has accumulated 9 data snapshots since 2019. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

~Oct 2019 – ~Jun 2020 · 8 months · monthly snapshotRecruiting~Jun 2020 – ~Jan 2021 · 7 months · monthly snapshotRecruiting~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshotRecruiting~Dec 2021 – ~Sep 2022 · 9 months · monthly snapshotActive Not Recruiting~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshotCompleted~Nov 2022 – ~Apr 2023 · 5 months · monthly snapshotCompleted~Apr 2023 – ~Jul 2024 · 15 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 24 months · monthly snapshotCompleted

Change History

9 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Apr 2023 — Jul 2024 [monthly]

    Completed PHASE2

  4. Nov 2022 — Apr 2023 [monthly]

    Completed PHASE2

  5. Sep 2022 — Nov 2022 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

▶ Show 4 earlier versions

  1. Dec 2021 — Sep 2022 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  2. Jan 2021 — Dec 2021 [monthly]

    Recruiting PHASE2

  3. Jun 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  4. Oct 2019 — Jun 2020 [monthly]

    Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Shanghai Pharmaceuticals Holding Co., Ltd
Data source: Shanghai Pharmaceuticals Holding Co., Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations